This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
=== Lyophilized === Lyophilized drugs are stored in vials, cartridges, dual chamber syringes, and prefilled mixing systems. Lyophilization, or freeze drying, is a process that removes water from a liquid drug creating a solid powder, or cake. The lyophilized product is stable for extended periods of time and could allow storage at higher temperatures. In protein formulations, stabilizers are added to replace the water and preserve the structure of the molecule. Before administration, a lyophilized drug is reconstituted as a liquid before being administered. This is done by combining a liquid diluent with the freeze-dried powder, mixing, then injecting. Reconstitution usually requires a reconstitution and delivery system to ensure that the drug is correctly mixed and administered.
For mass spectrometry analyses of a macromolecule, such as a protein, the analyte must be ionized and vaporized by laser irradiation. The problem is that the direct irradiation of an intense laser pulse on a macromolecule causes cleavage of the analyte into tiny fragments and the loss of its structure. In February 1985, Tanaka found that by using a mixture of ultra fine metal powder in glycerol as a matrix, an analyte can be ionized without losing its structure. His work was filed as a patent application in 1985, and after the patent application was made public reported at the Annual Conference of the Mass Spectrometry Society of Japan held in Kyoto, in May 1987 and became known as soft laser desorption (SLD). The obscure Tanaka had been at the second-lowest rank at Shimadzu when he won the Nobel Prize. The embarrassed company immediately promoted Tanaka to research fellow, and named a laboratory after him. However, there was some criticism about his winning the prize, saying that contribution by two German scientists, Franz Hillenkamp and Michael Karas was also big enough not to be dismissed, and therefore they should also be included as prize winners. This is because they first reported in 1985 a method, with higher sensitivity using a small organic compound as a matrix, that they named matrix-assisted laser desorption/ionization (MALDI). Also Tanaka's SLD is not used currently for biomolecules analysis, meanwhile MALDI is widely used in mass spectrometry research laboratories.
=== Pregnancy and breastfeeding === Research on animal reproduction has indicated that there is a trace of teratogenicity when doses are reduced by 10 times the human recommended dose. There is no sufficient information on human pregnancy at this moment. Use is only recommended when the potential benefits outweigh the potential risks for the pregnant mother and the fetus. Prednisolone when delivered systemically can be found in the mother's breast milk, however, there is no data provided for the extent of prednisolone found in the system after administering eye drops. However, the presence of corticosteroids is recorded when they are administered systemically, and it could affect the fetus' growth. Therefore, the use of prednisolone during breastfeeding is not advocated.
Sources: en.wikipedia.org
Mimoun "Rocky" Kaabouni, who was nicknamed "The Moroccan Escobar", was born in Ben Taïeb, a village in the province of Nador. He grew up in Hoensbroek, in the Netherlands, where he and his brother owned a coffeeshop named Happy Days. While often visiting Amsterdam, he eventually started meeting big names within the Moroccan mafia with whom he maintained regular contact. Mimoun left the Netherlands for southern Spain and Romania, where he founded his own criminal organisation made up of Lithuanians and Colombians. Mimoun, who was already bringing in tons of cocaine through the ports of Antwerp, Rotterdam, Amsterdam, and Algeciras, wanted to create a new route in Romania through the port of Constanța. He is currently serving a 19-year prison sentence in Romania for a record seizure of 2.5 tons of cocaine (the biggest seizure of cocaine in the country's history). Mimoun was arrested in 2016 when he tried to leave Spain through the Málaga Airport after the seizure in Romania, which was worth €600 million. It was one of the largest drug seizures in Eastern European history.
== Metal coordination == Being a type of molecules that are often only activated for biological and chemical function following metal-binding, the specific coordination of metal ions imposes certain restrictions and requirements onto metallopeptides. Usually metal cofactors are coordinated by nitrogen, oxygen or sulfur centers belonging to amino acid residues of the peptide. These donor groups can be introduced by histidine (or the corresponding imidazole), cysteine (thiolate group), as well as carboxylate substituents (e.g. by aspartate) but are not limited to these. The other amino acid residues, including non-natural amino acids and the peptide backbone have been shown to bind metal centers and provide donor groups. The research on metal-binding of peptides ranges from coordination of biometals (such as Calcium, Magnesium, Manganese, Zinc, Sodium, Potassium, and Iron) to heavy metals (such as Arsenic, Mercury, and Cadmium).
== External links == Fibronectin, an Extracellular Adhesion Molecule The Fibronectin Protein Fibronectin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Fibronectin molecular interactions Overview of all the structural information available in the PDB for UniProt: P02751 (Human Fibronectin) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P11276 (Mouse Fibronectin) at the PDBe-KB.
== Interactions == Doxepin should not be used within 14 days of using a monoamine oxidase inhibitor (MAOI) such as phenelzine due to the potential for hypertensive crisis or serotonin syndrome to develop. It is advised not to be used in those taking potent CYP2D6 inhibitors such as fluoxetine, paroxetine, sertraline, duloxetine, bupropion, and quinidine owing to the potential for its accumulation in the absence of full CYP2D6 catalytic activity. Hepatic enzyme inducers such as carbamazepine, phenytoin, and barbiturates are advised against in patients receiving TCAs like doxepin owing to the potential for problematically rapid metabolism of doxepin to occur in these individuals. Sympathomimetic agents may have their effects potentiated by TCAs like doxepin. Doxepin also may potentiate the adverse effects of anticholinergic agents such as benztropine, atropine and hyoscine (scopolamine). Tolazamide, when used in conjunction with doxepin has been associated with a case of severe hypoglycaemia in a type II diabetic individual. Cimetidine may influence the absorption of doxepin. Alcohol may potentiate some of the CNS depressant effects of doxepin. Antihypertensive agents may have their effects mitigated by doxepin. Cotreatment with CNS depressants such as the benzodiazepines can cause additive CNS depression. Co-treatment with thyroid hormones may also increase the potential for adverse reactions.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.